mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
mRNA-1273 COVID-19 vaccine effectiveness against the B.1.1.7 and B.1.351 variants and severe COVID-19 disease in Qatar
复制标题
DOI：
10.1038/s41591-021-01446-y
复制
发表时间：
2021-07-09
期刊：
影响因子：
82.9
通讯作者：
Abu-Raddad, Laith J.
中科院分区：
文献类型：
--
作者：
Chemaitelly, Hiam;Yassine, Hadi M.;Abu-Raddad, Laith J.
一项匹配的测试阴性病例对照研究使用了来自主要工作年龄人群的真实世界数据，证明mRNA-1273疫苗对B.1.1.7（Alpha）和B.1.351（Beta）SARS-CoV-2变异株的有效性分别为100%和96.4%。SARS-CoV-2大流行仍然是全球健康问题。据报道，在一项随机临床试验中，mRNA-1273（Moderna）疫苗在预防因感染“野生型”变异体而引起的症状性COVID-19方面的有效性为94.1%。在这里，我们评估了这种疫苗对关注的SARS-CoV-2变体的真实有效性，特别是B.1.1.7（Alpha）和B.1.351（Beta），在卡塔尔，主要包括工作年龄的成年人，使用匹配的测试阴性，病例对照研究设计。我们表明，疫苗的有效性是微不足道的第一剂后2周，但迅速增加，在第三和第四周前立即管理的第二剂。在第一次给药后第二次给药前≥ 14天，对B.1.1.7感染的有效性为88.1%（95%置信区间（CI）：83.7-91.5%），在第二次给药后≥ 14天，有效性为100%（95% CI：91.8-100.0%）。第一次给药后对B.1.351感染的类似有效性为61.3%（95% CI：56.5-65.5%），第二次给药后为96.4%（95% CI：91.9-98.7%）。首次和第二次给药后，对任何SARS-CoV-2感染（主要是B.1.1.7和B.1.351）引起的任何严重、危重或致死性COVID-19疾病的有效性分别为81.6%（95%CI：71.0-88.8%）和95.7%（95%CI：73.4-99.9%）。mRNA-1273疫苗对B.1.1.7和B.1.351感染非常有效，无论是有症状还是无症状，并对任何COVID-19住院和死亡都非常有效，即使是在单次接种后。
A matched test-negative, case-control study using real-world data from a predominantly working-age population demonstrates efficacy of the mRNA-1273 vaccine to be 100% and 96.4% against the B.1.1.7 (Alpha) and B.1.351 (Beta) SARS-CoV-2 variants of concern, respectively.The SARS-CoV-2 pandemic continues to be a global health concern. The mRNA-1273 (Moderna) vaccine was reported to have an efficacy of 94.1% at preventing symptomatic COVID-19 due to infection with 'wild-type' variants in a randomized clinical trial. Here, we assess the real-world effectiveness of this vaccine against SARS-CoV-2 variants of concern, specifically B.1.1.7 (Alpha) and B.1.351 (Beta), in Qatar, a population that comprises mainly working-age adults, using a matched test-negative, case-control study design. We show that vaccine effectiveness was negligible for 2 weeks after the first dose, but increased rapidly in the third and fourth weeks immediately before administration of a second dose. Effectiveness against B.1.1.7 infection was 88.1% (95% confidence interval (CI): 83.7-91.5%) >= 14 days after the first dose but before the second dose, and was 100% (95% CI: 91.8-100.0%) >= 14 days after the second dose. Analogous effectiveness against B.1.351 infection was 61.3% after the first dose (95% CI: 56.5-65.5%) and 96.4% after the second dose (95% CI: 91.9-98.7%). Effectiveness against any severe, critical or fatal COVID-19 disease due to any SARS-CoV-2 infection (predominantly B.1.1.7 and B.1.351) was 81.6% (95% CI: 71.0-88.8%) and 95.7% (95% CI: 73.4-99.9%) after the first and second dose, respectively. The mRNA-1273 vaccine is highly effective against B.1.1.7 and B.1.351 infections, whether symptomatic or asymptomatic, and against any COVID-19 hospitalization and death, even after a single dose.